A Phase 1 interventional study of AL001 and Placebo in Healthy and Frontotemporal Dementia, sponsored by Alector Inc.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-27.
Sponsored by Alector Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.
Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 31st largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2018, is one of 8 in phase 1, and was the 46th registered.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
Browse Frontotemporal Dementia studies →31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:
Institute for Molecular Medicine · Sites in United States
Ages 65–80
Maya Henry · Sites in United States
Ages 40+
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 45+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 5 · Phase 4 3
First in 2001; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.
Median enrollment 60 across the 66 interventional studies, 201 across the 37 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 103 have an industry lead sponsor. The 10 most frequent:
Alector Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Alector Inc. has 4 studies filed under Frontotemporal Dementia — fewer than ten, so there is no comparison to draw.
14 of the studies in Frontotemporal Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05262023Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | 2026-12 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05184569Peter Ljubenkov, MDVeri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | 2027-01-31 |
| NCT04516499The Bluefield Project to Cure Frontotemporal DementiaNeurofilament Surveillance Project (NSP) | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 103 studies in Frontotemporal Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK and PD of intravenously administered AL001 in Healthy Volunteers and FTD-GRN mutation carriers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to six single ascending doses of AL001
Biological: AL001
Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
Other: Placebo
Active dose of AL001
Saline solution administered as a single infusion as palcebo.
Evaluation of safety and tolerability of AL001 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)
Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.
Time frame: 85 days
Pharmacokinetics (PK) of AL001
Serum and cerebrospinal fluid (CSF) concentration of AL001 at specified time points
Time frame: 85 days
Maximum plasma concentration (Cmax) for AL001
Evaluate Cmax for serum and CSF concentration of AL001 at specified time points
Time frame: 85 days
Area under the curve concentration (AUC) for AL001
Evaluate AUC for serum and CSF concentration of AL001 at specified time points
Time frame: 85 days
Ran from Sep 2018 to primary completion in Dec 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Alector Inc.